Gilead Sciences, Inc.

NasdaqGS:GILD Stock Report

Market Cap: US$90.1b

Gilead Sciences Balance Sheet Health

Financial Health criteria checks 4/6

Gilead Sciences has a total shareholder equity of $22.7B and total debt of $25.0B, which brings its debt-to-equity ratio to 109.8%. Its total assets and total liabilities are $62.1B and $39.4B respectively. Gilead Sciences's EBIT is $9.3B making its interest coverage ratio 9.9. It has cash and short-term investments of $8.4B.

Key information

109.8%

Debt to equity ratio

US$24.99b

Debt

Interest coverage ratio9.9x
CashUS$8.35b
EquityUS$22.75b
Total liabilitiesUS$39.38b
Total assetsUS$62.13b

Recent financial health updates

Recent updates

Gilead's Business Development: The Good, The Bad, And The Spinning Kite Solution

Mar 01

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

Feb 28
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.77

We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Feb 15
We Think Gilead Sciences' (NASDAQ:GILD) Solid Earnings Are Understated

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Feb 13
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.77

Gilead Sciences: Cheap For A Reason

Feb 10

Gilead Sciences: The Sky Is Not Falling

Feb 01

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Jan 15
Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

Dec 25
What Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is Not Telling You

These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well

Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

Oct 10
Does Gilead Sciences (NASDAQ:GILD) Deserve A Spot On Your Watchlist?

We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Aug 11
We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt

Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

Jul 04
Here's Why Gilead Sciences (NASDAQ:GILD) Has Caught The Eye Of Investors

Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year

Jun 13
Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75

May 30
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75

Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75

May 16
Gilead Sciences (NASDAQ:GILD) Has Announced That It Will Be Increasing Its Dividend To $0.75

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

May 02
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet

Apr 17
Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Feb 21
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75

Feb 07
Gilead Sciences (NASDAQ:GILD) Will Pay A Larger Dividend Than Last Year At $0.75

Financial Position Analysis

Short Term Liabilities: GILD's short term assets ($16.1B) exceed its short term liabilities ($11.3B).

Long Term Liabilities: GILD's short term assets ($16.1B) do not cover its long term liabilities ($28.1B).


Debt to Equity History and Analysis

Debt Level: GILD's net debt to equity ratio (73.1%) is considered high.

Reducing Debt: GILD's debt to equity ratio has reduced from 126.9% to 109.8% over the past 5 years.

Debt Coverage: GILD's debt is well covered by operating cash flow (32%).

Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (9.9x coverage).


Balance Sheet


Discover healthy companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.